Hot Stocks: Baidu.com, Inc. (ADR)(NASDAQ:BIDU), NPS Pharmaceuticals, Inc.(NASDAQ:NPSP), Biogen Idec Inc.(NASDAQ:BIIB), Celldex Therapeutics, Inc. (NASDAQ:CLDX)
Baidu.com, Inc. (ADR)(NASDAQ:BIDU) shares jumped 1.39% to $129.33. The company on July 24, announced its unaudited financial results for the second quarter ended June 30, 2013. Total revenues in the second quarter of 2013 were RMB 7.561 billion ($1.232 billion), a 38.6% increase from the corresponding period in 2012. Net income attributable to Baidu in the second quarter of 2013 was RMB 2.644 billion ($430.8 million), a 4.5% decrease from the corresponding period in 2012. Diluted earnings attributable to Baidu per ADS for the second quarter of 2013 were RMB7.52 ($1.22); diluted earnings attributable to Baidu per ADS excluding share-based compensation expenses (non-GAAP) for the second quarter of 2013 were RMB7.75 ($1.26).
NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) shares declined 4.43% to $15.09. The company on May 28 reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 6,900,000, comprised of 6,000,000 shares of common stock initially offered and an additional 900,000 shares of common stock sold pursuant to the underwriters’ exercise of their over-allotment option, at the public offering price of $14.53 per share. Aggregate net proceeds to the company were approximately $93.4 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Biogen Idec Inc.(NASDAQ:BIIB) shares gained 1.98% to $219.47. BIIB’s stock was upgraded by Citigrooup from a “neutral” rating to a “buy” rating in a research note issued on June 28.
Additionally, the company was scheduled to showcase new data from a number of development and early-stage research programs at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress. Researchers will present 33 abstracts on clinical and pre-clinical research in hemophilia, the breadth of which reflects the company’s commitment to innovation and the scientific advancement of hemophilia treatment and care. The ISTH Congress will be held June 29 through July 4 in Amsterdam, The Netherlands.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares increased 3.86% to $20.43. Guggenheim assumed coverage on shares of CLDX in a research note issued to investors on July 5. The firm issued a buy rating and a $24.00 price target on the stock.